<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30207076</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2045-7634</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>7</Volume>                    <Issue>10</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                    </PubDate>                </JournalIssue>                <Title>Cancer medicine</Title>                <ISOAbbreviation>Cancer Med</ISOAbbreviation>            </Journal>            <ArticleTitle>Risk-based breast cancer follow-up stratified by age.</ArticleTitle>            <Pagination>                <MedlinePgn>5291-5298</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cam4.1760</ELocationID>            <Abstract>                <AbstractText>Although personalization of cancer care is recommended, current follow-up after the curative treatment of breast cancer is consensus-based and not differentiated for base-line risk. Every patient receives annual follow-up for 5 years without taking into account the individual risk of recurrence. The aim of this study was to introduce personalized follow-up schemes by stratifying for age. Using data from the Netherlands Cancer Registry of 37 230 patients with early breast cancer between 2003 and 2006, the risk of recurrence was determined for four age groups (&lt;50, 50-59, 60-69, &gt;70). Follow-up was modeled with a discrete-time partially observable Markov decision process. The decision to test for recurrences was made two times per year. Recurrences could be detected by mammography as well as by self-detection. For all age groups, it was optimal to have more intensive follow-up around the peak in recurrence risk in the second year after diagnosis. For the first age group (&lt;50) with the highest risk, a slightly more intensive follow-up with one extra visit was proposed compared to the current guideline recommendation. The other age groups were recommended less visits: four for ages 50-59, three for 60-69, and three for ≥70. With this model for risk-based follow-up, clinicians can make informed decisions and focus resources on patients with higher risk, while avoiding unnecessary and potentially harmful follow-up visits for women with very low risks. The model can easily be extended to take into account more risk factors and provide even more personalized follow-up schedules.</AbstractText>                <CopyrightInformation>© 2018 The Authors. Cancer Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Witteveen</LastName>                    <ForeName>Annemieke</ForeName>                    <Initials>A</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5581-6478</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Otten</LastName>                    <ForeName>Jan W M</ForeName>                    <Initials>JWM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Stochastic Operations Research, University of Twente, Enschede, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vliegen</LastName>                    <ForeName>Ingrid M H</ForeName>                    <Initials>IMH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Industrial Engineering and Innovation Sciences, Eindhoven University of Technology, Eindhoven, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Siesling</LastName>                    <ForeName>Sabine</ForeName>                    <Initials>S</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-0273-824X</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Timmer</LastName>                    <ForeName>Judith B</ForeName>                    <Initials>JB</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Stochastic Operations Research, University of Twente, Enschede, The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>IJzerman</LastName>                    <ForeName>Maarten J</ForeName>                    <Initials>MJ</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0001-5788-5805</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Faculty of Medicine, Dentistry and Health Sciences, School of Population and Global Health, University of Melbourne and Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>11</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Cancer Med</MedlineTA>            <NlmUniqueID>101595310</NlmUniqueID>            <ISSNLinking>2045-7634</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Med. 2018 Oct;7(10):5291-5298</RefSource>                <PMID Version="1">30207076</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Med Decis Making. 2010 Jul-Aug;30(4):474-83</RefSource>                <PMID Version="1">20044582</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2013 Apr;49(6):1374-403</RefSource>                <PMID Version="1">23485231</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2011 Feb 23;305(8):790-9</RefSource>                <PMID Version="1">21343578</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Surg. 1995 Oct;170(4):327-32</RefSource>                <PMID Version="1">7573723</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2009 Apr;114(3):403-12</RefSource>                <PMID Version="1">18421576</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Epidemiol. 2008 Jul 1;168(1):98-104</RefSource>                <PMID Version="1">18504245</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2006 Jun 7;98(11):774-82</RefSource>                <PMID Version="1">16757702</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMJ. 2009 Jan 14;338:a3147</RefSource>                <PMID Version="1">19147478</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg Oncol. 2015 Dec;22 Suppl 3:S522-8</RefSource>                <PMID Version="1">25986872</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Med Decis Making. 1993 Oct-Dec;13(4):322-38</RefSource>                <PMID Version="1">8246705</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2015 Aug;152(3):627-36</RefSource>                <PMID Version="1">26162567</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Intern Med. 1992 May 1;116(9):722-30</RefSource>                <PMID Version="1">1558343</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Manuf Serv Oper Manag. 2012 Apr;14(4):600-617</RefSource>                <PMID Version="1">24027436</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Radiology. 2002 Oct;225(1):165-75</RefSource>                <PMID Version="1">12355001</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2013 Jun 13;13:283</RefSource>                <PMID Version="1">23763955</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Oncol Nurs. 2000 Sep;4(3):138-45; discussion 146-7</RefSource>                <PMID Version="1">12849643</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2017 Oct;165(3):709-720</RefSource>                <PMID Version="1">28677011</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2012 Dec;136(3):859-68</RefSource>                <PMID Version="1">23117854</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">follow-up</Keyword>            <Keyword MajorTopicYN="N">locoregional recurrence</Keyword>            <Keyword MajorTopicYN="N">partially observable Markov decision process</Keyword>            <Keyword MajorTopicYN="N">second primary</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>14</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>07</Month>                <Day>15</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>13</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30207076</ArticleId>            <ArticleId IdType="doi">10.1002/cam4.1760</ArticleId>            <ArticleId IdType="pmc">PMC6198239</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>